公司資料
Cue Biopharma Inc 股價、新聞與催化劑
- 股票代碼:
- CUE
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
27.64 USD (-19.18%)
收盤價
最後更新: 2026年8月17日
116M USD
市值
股價為何變動
Following the latest company update, “Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights”, CUE closed down 19.2% at $27.64 on Aug 17, 2026. The move occurred in the trading session associated with this earnings update.
公司概覽
Immune-Mediated Disease Portfolio
Cue Biopharma is a clinical-stage biotechnology company developing therapies for allergic and autoimmune diseases. Its portfolio combines a conventional antibody program with an Immuno-STAT platform designed to selectively regulate disease-driving immune cells.
CUE-221
CUE-221 is a dual-mechanism anti-IgE antibody being developed for allergic diseases. The program is in Phase 2 development for chronic spontaneous urticaria, while the company has also submitted an investigational new drug application to evaluate the candidate in food allergy.
Immuno-STAT Platform
The Immuno-STAT platform is designed to engage selected T-cell populations in vivo rather than broadly suppressing the immune system. Cue is applying the platform to autoimmune disease with the goal of reducing inflammation while promoting regulatory T-cell-mediated immune tolerance.
CUE-401
CUE-401 is the company's lead autoimmune Immuno-STAT candidate. It is designed to expand and activate regulatory T cells associated with control of inflammatory responses and is advancing toward first-in-human development.
未來催化劑
- Phase 2 CUE-221 data in chronic spontaneous urticaria by the end of Q3 2026.
- IND submission for CUE-401 by year-end 2026.
- Initiation of a Phase 1 study of CUE-401 by year-end 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。